2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patients
2005
Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas
Chen G, Bhojani M, Heaford A, Chang D, Laxman B, Thomas D, Griffin L, Yu J, Coppola J, Giordano T, Lin L, Adams D, Orringer M, Ross B, Beer D, Rehemtulla A. Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 12507-12512. PMID: 16109772, PMCID: PMC1194899, DOI: 10.1073/pnas.0500397102.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinomaApoptosisCell CycleCell NucleusCell ProliferationDNA, NeoplasmElectrophoresis, Gel, Two-DimensionalFas-Associated Death Domain ProteinGene AmplificationGene ExpressionHumansJurkat CellsLung NeoplasmsMutationNF-kappa BOligonucleotide Array Sequence AnalysisPhosphorylationPrognosisRNA, MessengerRNA, NeoplasmRNA, Small InterferingSerineConceptsFas-associated death domainCell cycle progressionP-FADDCell cyclePhosphorylated Fas associated death domainAnalysis of copy numberRegulation of cell cycle progressionNF-kappaB activationNF-kappaBPerturbed cell cycleElevated NF-kappaBCDNA microarray analysisInduction of NF-kappaB activityFADD geneDeath domainNonphosphorylatable formPoor outcomeLung cancerCDNA microarrayLung adenocarcinomaNuclear localizationCycle progressionCopy numberTissue microarray analysisAssociated with poor survival